Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872153 | 0.87 | MCL1 (0.45) | MCL1CA12CA1CA9MTNR1A | |
| SCHEMBL25338022 | 0.80 | HTR7 (0.44) | MCL1HDAC6KDM4EALDH1A1 | |
| SCHEMBL1750249 | 0.80 | CA12 (0.44) | MCL1CA12CA1CA9KDM4E | |
| SCHEMBL5023905 | 0.79 | MCL1 (0.41) | MCL1HDAC6MTNR1AMTNR1BPPARG | |
| SCHEMBL5023879 | 0.79 | ABCG2 (0.38) | CA12CA1CA9HDAC6KDM4E | |
| SCHEMBL3874157 | 0.78 | PPARD (0.42) | CA12CA1CA9MTNR1AMTNR1B | |
| SCHEMBL3057043 | 0.78 | MCL1 (0.41) | MCL1HDAC6MTNR1AMTNR1BPPARG | |
| SCHEMBL5025466 | 0.74 | LOXL2 (0.40) | HDAC6PPARGPPARDPPARAKDM4E | |
| SCHEMBL30229742 | 0.74 | KMT2A (0.59) | KDM4EALDH1A1 | |
| SCHEMBL3597779 | 0.74 | KMT2A (0.59) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725546-B1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| EP-1644368-B1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-7265149-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7235572-B2 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1725546-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| EP-1682535-A1 | HETEROARYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| EP-1644368-A1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-6995263-B2 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050203160-A1 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | disclosed |
| WO-2005085235-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005049606-A1 | HETEROARYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005005423-A1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203160-A1 | Indolyl derivatives | PPARD, PPARA, PPARG | MCL1 2737/4885CA12 4878/4885CA1 4860/4885 |
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | MCL1 2082/4885CA12 4869/4885CA1 4852/4885 |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | MCL1 2700/4885CA12 4870/4885CA1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.